CIK 0001674416
- Large accelerated filer
CRISPR Therapeutics AG
Sign in to watch- Ticker
- CRSP
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- Switzerland
- Entity type
- Operating
- EIN
- 473173478
- Phone
- +1 617-315-4600
- Business address
- BAARERSTRASSE 14, ZUG, Switzerland
- Former names
- CRISPR Therapeutics AG
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,881,673
- in 7 filings, $1.5M under 10b5-1 plans
Net −$4,881,673. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2017-04-20 | Kulkarni Samarth Chief Business Officer | Exercise or conversion · Stock Options (Right to Buy) | −2,800 | 311,654 | ||
| 2017-04-20 | Dylan-Hyde Tyler Chief Legal Officer | Sale | −2,937 | $17.37 | $51K | 195,027 |
| 2017-04-19 | Novak Rodger Chief Executive Officer | Exercise or conversion | +47,706 | $1.81 | $86K | 1,262,711 |
| 2017-04-19 | Novak Rodger Chief Executive Officer | Sale | −32,338 | $17.57 | $568K | 1,230,373 |
| 2017-04-19 | Novak Rodger Chief Executive Officer | Sale | −15,368 | $18.61 | $286K | 1,215,005 |
| 2017-04-19 | Novak Rodger Chief Executive Officer | Exercise or conversion · Stock Options (Right to Buy) | −47,706 | 220,387 | ||
| 2017-04-19 | Kulkarni Samarth Chief Business Officer | Exercise or conversion | +7,258 | $1.81 | $13K | 141,305 |
| 2017-04-19 | Kulkarni Samarth Chief Business Officer | Sale | −4,809 | $17.54 | $84K | 136,496 |
| 2017-04-19 | Kulkarni Samarth Chief Business Officer | Sale | −2,449 | $18.54 | $45K | 134,047 |
| 2017-04-19 | Kulkarni Samarth Chief Business Officer | Exercise or conversion · Stock Options (Right to Buy) | −7,258 | 314,454 | ||
| 2017-04-19 | Dylan-Hyde Tyler Chief Legal Officer | Sale | −4,930 | $17.49 | $86K | 200,274 |
| 2017-04-19 | Dylan-Hyde Tyler Chief Legal Officer | Sale | −2,310 | $18.58 | $43K | 197,964 |
| 2016-10-24 | EMSTER KURT VON Director | Conversion | +2,354,050 | 2,354,050 | ||
| 2016-10-24 | EMSTER KURT VON Director | Conversion | +191,764 | 2,545,814 | ||
| 2016-10-24 | EMSTER KURT VON Director | Purchase | +56,000 | $14.00 | $784K | 2,601,814 |
| 2016-10-24 | EMSTER KURT VON Director | Conversion · Series A-3 Preferred Shares | −2,354,050 | 0 | ||
| 2016-10-24 | EMSTER KURT VON Director | Conversion · Series B Preferred Shares | −191,764 | 0 | ||
| 2016-10-24 | Lundberg Sven Ante Chief Scientific Officer | Conversion | +55,217 | 505,217 | ||
| 2016-10-24 | Lundberg Sven Ante Chief Scientific Officer | Purchase | +400 | $14.00 | $6K | 505,617 |
| 2016-10-24 | Lundberg Sven Ante Chief Scientific Officer | Conversion · Series B Preferred Shares | −55,217 | 0 |
Page 67 of 74 · 1,471 trades